Home > DOACs and bleeding: the role of antidotes

DOACs and bleeding: the role of antidotes

Presented By
Dr Kaveshree Govender, Milpark Hospital, South Africa
EHRA 2021
The use of direct oral anticoagulants (DOACs) in patients with atrial fibrillation is associated with the risk of bleeding complications. To manage severe and life-threatening bleeding, specific antidotes have become available that can effectively restore haemostasis. Major bleeding in patients with atrial fibrillation medicated with factor Xa (FXa) and factor IIa (FIIa) inhibitors is still a concern. The major limitation was the lack of specific reversal agents. However, antidotes have now become available and Dr Kaveshree Govender (Milpark Hospital, South Africa) presented their role in managing bleeding complications [1]. The 2018 EHRA practical guideline on atrial fibrillation provided guidance on managing bleeding episodes in DOAC-treated patients: delay or discontinuation of DOAC treatment in mild bleeding, symptomatic treatment in non-life-threatening major bleeding with or without antidote-treatment, and finally antidote-treatment in life-t...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on